VANCOUVER, British Columbia, Oct. 22, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that it has completed its previously announced underwritten public offering of 3,750,000 shares of its common stock, at a public offering price of $8.00 per share, representing gross proceeds of US$30.0 million. The underwriters have been granted a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the public offering to cover over-allotments.
Help employers find you! Check out all the jobs and post your resume.
